Prehn’s sign is a physical exam finding that is often used to help diagnose appendicitis. It was first described in 1771 by Dutch physician Abraham Prehn, but the exact mechanism of the sign is still not fully understood. In this comprehensive guide, we will explore the history, mechanism, and clinical utility of Prehn’s sign. We will also discuss potential limitations and alternative methods for diagnosing appendicitis.
Prehn’s sign is named after Abraham Prehn, the Dutch physician who first described the sign in 1771. Prehn noted that when the right lower quadrant of the abdomen was pressed upon, the pain associated with appendicitis was relieved. This finding was later confirmed by other physicians, including John Hunter and Sir Astley Cooper.
The exact mechanism of Prehn’s sign is still not fully understood. It is believed that the pressure exerted on the right lower quadrant of the abdomen compresses the appendix, which in turn reduces the pain associated with appendicitis. This is thought to be due to the fact that the appendix is a hollow organ and is easily compressed.
Prehn’s sign is often used to help diagnose appendicitis. A positive Prehn’s sign is typically indicative of appendicitis, although it is not always reliable. Other signs and symptoms, such as fever, nausea, vomiting, and abdominal tenderness, should also be taken into account when diagnosing appendicitis. In addition, Prehn’s sign has been used to help diagnose other conditions, such as ectopic pregnancy, ovarian cysts, and pelvic inflammatory disease. However, the reliability of the sign for these conditions is not as well established as it is for appendicitis.
Although Prehn’s sign is often used to help diagnose appendicitis, it is not always reliable. The sign may be falsely positive or negative in some cases, and it is not as reliable in children or the elderly. Additionally, the sign may be difficult to interpret in patients who are obese or have other abdominal conditions.
In addition to Prehn’s sign, there are several other methods for diagnosing appendicitis. These include laboratory tests, imaging studies, and laparoscopy. Laboratory tests such as complete blood count and urinalysis can help identify certain markers of inflammation, which may indicate appendicitis. Imaging studies such as ultrasound and CT scan can help visualize the appendix and identify any abnormalities. Laparoscopy is a surgical procedure that can be used to directly visualize the appendix and make a definitive diagnosis.
Prehn’s sign is a physical exam finding that is often used to help diagnose appendicitis. It was first described in 1771 by Dutch physician Abraham Prehn, but the exact mechanism of the sign is still not fully understood. In this comprehensive guide, we have explored the history, mechanism, and clinical utility of Prehn’s sign. We have also discussed potential limitations and alternative methods for diagnosing appendicitis. While Prehn’s sign can be a useful tool for diagnosing appendicitis, it is important to note that it is not always reliable and should not be used as the sole method of diagnosis.
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation